摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

淫羊霍定C | 110642-44-9

中文名称
淫羊霍定C
中文别名
淫羊藿苷C;宝藿苷VI;朝藿定C;养霍定C;淫羊藿定C;朝藿定 C;淫羊藿定 C
英文名称
epimedin C
英文别名
3-[(2S,3R,4R,5R,6S)-4,5-dihydroxy-6-methyl-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-enyl)-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one
淫羊霍定C化学式
CAS
110642-44-9
化学式
C39H50O19
mdl
——
分子量
822.815
InChiKey
ULZLIYVOYYQJRO-JIYCBSMMSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    179-180 °C(Solv: methanol (67-56-1))
  • 沸点:
    1062.1±65.0 °C(Predicted)
  • 密度:
    1.57±0.1 g/cm3(Predicted)
  • 溶解度:
    可溶于DMSO(少许)、甲醇(少许)
  • 最大波长(λmax):
    313nm(EtOH)(lit.)

计算性质

  • 辛醇/水分配系数(LogP):
    0.6
  • 重原子数:
    58
  • 可旋转键数:
    11
  • 环数:
    6.0
  • sp3杂化的碳原子比例:
    0.56
  • 拓扑面积:
    293
  • 氢给体数:
    10
  • 氢受体数:
    19

安全信息

  • 海关编码:
    29329990
  • WGK Germany:
    3
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335

制备方法与用途

朝藿定C具有治疗心血管疾病和骨质流失的潜力。这是一种天然化合物,源自巫山淫羊藿,被用作中药中的保健品。在切除卵巢的小鼠体内,朝藿定C表现出与雌性激素相似的作用。

化学性质

朝藿定C是一种黄色结晶粉末,可溶于甲醇、乙醇和DMSO等有机溶剂。

用途

朝藿定C可用于麻醉前给药以减少腺体分泌,治疗震颤麻痹及晕动症。此外,它还可用于含量测定、鉴定以及药理实验。其具有广泛的药理作用,包括抗骨质疏松、抗癌和免疫增强等。

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    淫羊霍定C 在 Cunninghamella blakesleana 作用下, 以 甲醇 为溶剂, 反应 120.0h, 以97.7%的产率得到2''-O-rhamnosylicariside
    参考文献:
    名称:
    Biotransformation of major flavonoid glycosides in herb epimedii by the fungus Cunninghamella blakesleana
    摘要:
    Biotransformation of icariin (1), epimedin C (2), epimedoside A (3), epimedin A (4) and epimidin B (5), five major components of E. koreanum, were performed by using Cunninghamella blakesleana. And they could be metabolized efficiently to icariside II (1a), 2 ''-O-rhamnosylikarisoside II (2a), epimedoside b (3a), baohuoside VII (4a) and sagittatoside B (5a) with high yields of 95.1%, 97.7%, 93.7%, 95.8% and 96.4%, respectively. And these transformed products as major forms of herb epimedii in vivo exhibited the more significant anti-osteoporosis activities. Our method could be applied for enriching these rare flavonoids in herb epimedii, for further development of anti-osteoporosis medicines or functional foods. (C) 2015 Published by Elsevier B.V.
    DOI:
    10.1016/j.molcatb.2015.05.021
点击查看最新优质反应信息

文献信息

  • Obesity small molecules
    申请人:Akron Molecules GmbH
    公开号:EP2633884A1
    公开(公告)日:2013-09-04
    The present invention relates to new therapies to treat obesity and related diseases, as well as for reducing triglyceride levels and body weight.
    本发明涉及治疗肥胖症和相关疾病以及降低甘油三酯水平和体重的新疗法。
  • DRUG FOR TREATING LEUKOPENIA, PREPARATION METHOD THEREFOR AND USE THEREOF
    申请人:Hubei Monyan Pharmaceutical Co., Ltd.
    公开号:EP3888670A1
    公开(公告)日:2021-10-06
    The present invention relates to a drug for treating leukopenia, its preparation method and use thereof. The drug of the invention is prepared from 200-30 parts by weight of Folium Epimedii,100-160 parts by weight of Fructus Psoraleae, 60-120 parts by weight of Radix Aconiti Lateralis Preparata (Processed), 200-300 parts by weight of Fructus Lycii, 200-300 parts by weight of Radix Astragali, 200-300 parts by weight of Caulis Spatholobi, 200-300 parts by weight of Radix Rubiae,100-160 parts by weight of Radix Angelicae Sinensis, 200-300 parts by weight of Rhizoma Phragmitis, 100-160 parts by weight of Radix Ophiopogonis and 100-160 parts by weight of Radix et Rhizoma Glycyrrhizae. The drug of the invention comprises chemical substances with weight ratios as follows:Leucine: guanosine: psoralenoside: isopsoralenoside: calycosin-7-glucoside: liquiritin: icariin A: 1,3-dihydroxyl-2-hydroxymethylanthraquinone: epimedin A: epimedin B: epimedin C: icariin: 1,3,6-trihydroxy-2-methylanthraquinone: glycyrrhizic acid = (0.13-0.27): (0.04-0.11): (0.11-0.34): (0.09-0.34): (0.05-0.11): (0.16-0.26): (0.09-0.12): (0.17-0.35): (0.11-0.16): (0.17-0.26): (0.49-0.59): 1.00: (0.16-0.24): (0.08-0.14).
    本发明涉及一种治疗白细胞减少症的药物及其制备方法和用途。本发明的药物由以下重量份数的原料制备而成:200-30 份 Epimedii、100-160 份 Psoraleae、60-120 份 Radix Aconiti Lateralis Preparata(加工)、200-300 份 Fructus Lycii、200-300 份 Radix Astragali、200-300 份(按重量计)麦冬、200-300 份(按重量计)茜草、100-160 份(按 重量计)当归、200-300 份(按重量计)黄芪、100-160 份(按重量计)麦冬和 100-160 份(按重量计)甘草。本发明的药物由重量比如下的化学物质组成:亮氨酸:鸟苷:补骨脂苷:异补骨脂苷:钙苷-7-葡萄糖苷:利奎林:冰片苷 A:1,3-二羟基-2-羟甲基蒽醌:附子苷 A:附子苷 B:附子苷 C:冰片苷:1,3,6-三羟基-2-甲基蒽醌:甘草酸 = (0.13-0.27): (0.04-0.11):(0.11-0.34): (0.09-0.34): (0.05-0.11):(0.16-0.26): (0.09-0.12): (0.17-0.35): (0.11-0.16): (0.17-0.26): (0.49-0.59):1.00: (0.16-0.24):(0.08-0.14).
  • [EN] METHOD FOR PREPARING BAOHUOSIDE I BY USING β-GLUCOSIDASE<br/>[FR] PROCÉDÉ DE PRÉPARATION DE BAOHUOSIDE I AU MOYEN DE β-GLUCOSIDASE<br/>[ZH] 一种利用β-葡萄糖苷酶制备宝藿苷I的方法
    申请人:BONTAC BIO ENG SHENZHEN CO LTD
    公开号:WO2019205025A1
    公开(公告)日:2019-10-31
    一种制备宝藿苷I的方法,包括利用β-葡萄糖苷酶催化底物水解制备宝藿苷I,所述底物为淫羊藿提取物、淫羊藿苷、朝藿定A、朝藿定C、箭藿苷A和箭藿苷B中的任意一种或多种,所述β-葡萄糖苷酶由来源于极端栖热袍菌 Thermotoga petrophila RKU-1的β-葡萄糖苷酶基因编码。
  • Efficient preparation of icariin from epimedin C by recyclable biphasic enzymatic hydrolysis
    作者:Wang Chen、Yue Zhang、Yuhang Zhang、Zili Feng、Xu He
    DOI:10.1080/14786419.2024.2340057
    日期:——
    Icariin is the most bioactive ingredient of Epimedium L. and a quality marker of Herba Epimedii. Conventional methods for production of Icariin are known to be inefficient, resulting in low yields ...
    淫羊藿苷是淫羊藿中最具生物活性的成分,也是淫羊藿的质量标志物。众所周知,传统的淫羊藿苷生产方法效率低下,导致产量低......
  • OBESITY SMALL MOLECULES
    申请人:Akron Molecules GmbH
    公开号:EP2521594A2
    公开(公告)日:2012-11-14
查看更多